The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …

Chimeric antigen receptor (CAR) T cell therapy is revolutionizing cancer immunotherapy for
patients with B cell malignancies and is now being developed for solid tumors and chronic …

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in
many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within …

Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a
result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate …

Chimeric antigen receptor (CAR) T cell therapy is effective in lymphoid malignancies, but
there has been limited data in myeloid cancers. Here, we start with a CD27-based CAR to …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)‐modified T cells can
induce durable remissions in patients with refractory B‐lymphoid cancers. By contrast …